Clinical outcomes associated with coadministration of lopinavir/ritonavir-based ART and rifampicin-containing TB treatment.

<p>T-test, Chi-square, and Fisher’s tests used for comparisons, * p<0.05.</p

Kaplan-Meier survival curve for the impact of lopinavir/ritonavir dosing strategy among patients with HIV/TB coinfection on time until treatment discontinuation.

<p>Kaplan-Meier survival curve for the impact of lopinavir/ritonavir dosing strategy among patients with HIV/TB coinfection on time until treatment discontinuation.</p

Baseline characteristics of patients at initiation of lopinavir/ritonavir-based second line ART, according to treatment group.

<p>Baseline characteristics of patients at initiation of lopinavir/ritonavir-based second line ART, according to treatment group.</p

Resistance profile of Gram-positive bacteria.

<p>Resistance profile of Gram-positive bacteria.</p

General bacteria etiology among blood culture isolates.

<p>General bacteria etiology among blood culture isolates.</p

Map of Iraq showing area of Sulaymaniyah.

<p>Map of Iraq showing area of Sulaymaniyah.</p

Resistance profile for gram-negative bacteria.

<p>Resistance profile for gram-negative bacteria.</p

CD4 count outcomes at 12 and 30 months based on patient demographic and pre-HAART characteristics.

<p>CD4 count outcomes at 12 and 30 months based on patient demographic and pre-HAART characteristics.</p

CD4+ T-cell count trajectories and baseline characteristics predicting failure of CD4 cell count recovery.

<p><b>A</b>. CD4+ T-cell count trajectories for all 442 subjects over the course of 30 months. The red line reflects the median±SEM. <b>B</b>. OR and 95% confidence intervals (CI) for not achieving CD4 counts above 200 cells/mm³ at 12 months (grey) and 500 cells/mm³ at 30 months (black) depending on baseline characteristics. Shown are only factors with significant or close to significant effect in the multivariate model.</p